46 completed, 11 terminated, 7 active not recruiting, 5 recruiting. 75 Phase 2, 16 Phase 1, 1 Phase 3.
Follow Leukemia, Hairy Cell: new trials by email Literature Review of Leukemia, Hairy Cell trials Research Report on Leukemia, Hairy Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant Zanubrutinib - Hairy Cell Leukemia, Hairy Cell Leukemia Variant | Phase 2 | Enrolling by invitation | Bnai Zion Medical Center | 12 | 2026-06-01 | 2026-07-08 |
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2026-05-29 | 2026-07-31 |
| Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2024-12-16 | 2026-09-09 |
| A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL) Vemurafenib, Obinutuzumab, Cladribine - Hairy Cell Leukemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 86 | 2024-09-09 | 2026-09-09 |
| Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies Brexucabtagene Autoleucel, Cyclophosphamide, Fludarabine - Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation | Phase 2 | Terminated | Kite, A Gilead Company | 19 | 2022-11-01 | 2026-03-10 |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma Epcoritamab, Lenalidomide, Ibrutinib - Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | Genmab | 264 | 2022-06-14 | 2026-07-07 |
| Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia Low dose vemurafenib plus rituximab - Hairy Cell Leukemia | Phase 2 | Completed | Scripps Health | 15 | 2022-03-02 | 2026-04-24 |
| Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant binimetinib - Hairy Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 40 | 2021-01-07 | 2026-10-16 |
| Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL binimetinib, Encorafenib - Hairy Cell Leukemia | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 28 | 2020-10-28 | 2026-06-12 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Withdrawn | City of Hope Medical Center | 2020-10-20 | 2020-12-17 | |
| A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia Vemurafenib, Obinutuzumab - Hairy Cell Leukemia, Leukemia | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2018-02-09 | 2026-08-24 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab - Anemia, B-Cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Alexey Danilov, MD | 24 | 2017-07-17 | 2023-08-08 |
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma rituximab, lenalidomide, romidepsin - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2016-10-01 | 2016-08-11 | |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Acalabrutinib, Pembrolizumab - Follicular Lymphoma (FL), CLL | Phase 1 / Phase 2 | Completed | Acerta Pharma BV | 161 | 2015-02-20 | 2026-05-13 |
| Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Dabrafenib, Trametinib - Cancer | Phase 2 | Completed | Novartis Pharmaceuticals | 206 | 2014-03-12 | 2023-08-21 |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies cyclophosphamide, fludarabine phosphate, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 2 | Withdrawn | University of Medicine and Dentistry of New Jersey | 2014-01-01 | 2016-07-14 | |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies vorinostat, tacrolimus, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2013-06-01 | 2018-07-24 |
| Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Hairy Cell Leukemia Variant | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 44 | 2013-04-30 | 2026-09-15 |
| Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies therapeutic allogeneic lymphocytes, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 2 | Completed | University of Chicago | 77 | 2013-04-04 | 2019-08-07 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
Showing 20 of 75. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (51) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (50) · Burkitt Lymphoma (47) · Lymphoma, B-Cell, Marginal Zone (47) · Lymphoma, Follicular (47) · Lymphoma, Mantle-Cell (46) · Lymphoma, Non-Hodgkin (46) · Hodgkin Disease (45) · Lymphoma, Large B-Cell, Diffuse (45) · Lymphoma, Large-Cell, Immunoblastic (44) · Multiple Myeloma (40) · Lymphoma, T-Cell, Cutaneous (37) · Leukemia, Myeloid, Acute (36) · Mycosis Fungoides (33)
Hematologic Diseases (75) · Hemic and Lymphatic Diseases (75) · Immune System Diseases (75) · Immunoproliferative Disorders (75) · Lymphatic Diseases (75) · Neoplasms by Histologic Type (75) · Lymphoproliferative Disorders (70) · Neoplasms (69) · Pathologic Processes (56) · Pathological Conditions, Signs and Symptoms (56) · Disease Attributes (54) · Chronic Disease (52) · Leukemia, Lymphoid (52) · Lymphoma, B-Cell (52) · Leukemia, B-Cell (51)
Rituximab (16) · Peripheral Blood Stem Cell Transplantation (13) · Tacrolimus (12) · Mycophenolic Acid (11) · fludarabine phosphate (10) · Cyclophosphamide (8) · Whole-Body Irradiation (8) · Cyclosporine (7) · Methotrexate (6) · Antilymphocyte Serum (5) · Cladribine (5) · Busulfan (4) · Methylprednisolone (4) · Vemurafenib (4) · Alemtuzumab (3)
Fred Hutchinson Cancer Center (16) · National Cancer Institute (NCI) (15) · Memorial Sloan Kettering Cancer Center (3) · Cancer Treatment Centers of America (2) · City of Hope Medical Center (2) · M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · National Institutes of Health Clinical Center (CC) (2) · Northwestern University (2) · Acerta Pharma BV (1) · Alexey Danilov, MD (1) · Asan Medical Center (1) · Barbara Ann Karmanos Cancer Institute (1) · Bnai Zion Medical Center (1) · Case Comprehensive Cancer Center (1)
United States (64) · Italy (8) · Germany (7) · France (5) · Netherlands (3) · South Korea (3) · Spain (3) · Switzerland (3) · Austria (2) · Belgium (2) · Canada (2) · Denmark (2) · Israel (2) · Japan (2) · China (1)
Robert J Kreitman, M.D. (6) · Brenda Sandmaier (3) · David Maloney (3) · Jae Park, MD (2) · Mathias J Rummel, Prof. Dr. (2) · Adam Petrich, MD (1) · Alan Saven, MD (1) · Albert von Rohr, MD (1) · Anastasios Raptis, MD (1) · Ann Traynor, MD (1) · Antonio T. Fojo, MD, PhD (1) · Charles L. Loprinzi, M.D. (1) · Claudio Anasetti, MD (1)
PMID 32499241, PMID 18596230, PMID 18327587, PMID 18603561, PMID 18989154, PMID 19170225, PMID 19841031, PMID 19900571, PMID 21821712, PMID 25092772, PMID 26213141, PMID 26352686, PMID 28314788, PMID 29072975, PMID 31481800, PMID 32109194, PMID 32818466, PMID 33754642, PMID 34196037, PMID 34607348, PMID 34838156, PMID 35930750, PMID 36108341, PMID 37059834, PMID 37219859, PMID 37934000, PMID 38320179, PMID 41060318, PMID 41980020, PMID 42308249
P30CA015704 (7), P01CA018029 (3), P01CA078902 (3), P30CA015083 (3), N01CM00039 (2), N01CM62202 (2), P30CA016058 (2), UM1CA186712 (2), 2023 (1), P30CA008748 (1), P30CA016672 (1), P30CA022453 (1), P30CA036727 (1), P30CA043703 (1), P30CA046592 (1)